These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 33068194)

  • 21. Clinical effect of immunophenotyping on the prognosis of multiple myeloma patients treated with bortezomib.
    Iriyama N; Miura K; Hatta Y; Kobayashi S; Uchino Y; Kurita D; Sakagami H; Takahashi H; Sakagami M; Kobayashi Y; Nakagawa M; Ohtake S; Iizuka Y; Takei M
    Oncol Lett; 2017 May; 13(5):3803-3808. PubMed ID: 28521480
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Morphologic Classification Is an Important Prognostic Factor in Patients with Newly Diagnosed Multiple Myeloma Treated with Bortezomib or Lenalidomide.
    Takakuwa T; Araki T; Nakamura K; Fukuyama T; Miura A; Fujitani Y; Hisanabe A; Kaieda A; Fukada E; Yamamura R
    Ann Clin Lab Sci; 2020 May; 50(3):333-341. PubMed ID: 32581022
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
    Richardson PG; Oriol A; Beksac M; Liberati AM; Galli M; Schjesvold F; Lindsay J; Weisel K; White D; Facon T; San Miguel J; Sunami K; O'Gorman P; Sonneveld P; Robak P; Semochkin S; Schey S; Yu X; Doerr T; Bensmaine A; Biyukov T; Peluso T; Zaki M; Anderson K; Dimopoulos M;
    Lancet Oncol; 2019 Jun; 20(6):781-794. PubMed ID: 31097405
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment Patterns and Clinical and Economic Outcomes in Patients With Newly Diagnosed Multiple Myeloma Treated With Lenalidomide- and/or Bortezomib-containing Regimens Without Stem Cell Transplant in a Real-world Setting.
    Chari A; Parikh K; Ni Q; Abouzaid S
    Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):645-655. PubMed ID: 31377207
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adhesion molecules on human myeloma cells: significant changes in expression related to malignancy, tumor spreading, and immortalization.
    Pellat-Deceunynck C; Barillé S; Puthier D; Rapp MJ; Harousseau JL; Bataille R; Amiot M
    Cancer Res; 1995 Aug; 55(16):3647-53. PubMed ID: 7543019
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD56 expression in multiple myeloma: Correlation with poor prognostic markers but no effect on outcome.
    Koumpis E; Tassi I; Malea T; Papathanasiou K; Papakonstantinou I; Serpanou A; Tsolas E; Kapsali E; Vassilakopoulos TP; Papoudou-Bai A; Hatzimichael E
    Pathol Res Pract; 2021 Sep; 225():153567. PubMed ID: 34352440
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proliferation of immature myeloma cells by interleukin-6 is associated with CD45 expression in human multiple myeloma.
    Ishikawa H; Mahmoud MS; Fujii R; Abroun S; Kawano MM
    Leuk Lymphoma; 2000 Sep; 39(1-2):51-5. PubMed ID: 10975383
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of prior bortezomib therapy on the incidence of lenalidomide-induced skin rash in multiple myeloma: a propensity score-matched multi-institutional cohort study.
    Dote S; Ito K; Itakura S; Yasu T; Hira D; Noda S; Yamada S; Kobayashi Y; Terada T
    Leuk Lymphoma; 2019 Dec; 60(12):2975-2981. PubMed ID: 31046497
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Retrospective Analysis of Bortezomib or Lenalidomide for Very Elderly Patients with Newly Diagnosed Multiple Myeloma].
    Okayama Y; Takakuwa T; Otomaru I; Horiuchi M; Miura A; Araki T; Fujitani Y; Yamamura R
    Gan To Kagaku Ryoho; 2021 Jun; 48(6):815-819. PubMed ID: 34139730
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatitis B Reactivation Rate and Fate Among Multiple Myeloma Patients Receiving Regimens Containing Lenalidomide and/or Bortezomib.
    Ataca Atilla P; Yalçıner M; Atilla E; İdilman R; Beksaç M
    Turk J Haematol; 2019 Nov; 36(4):266-273. PubMed ID: 31368290
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of bone-modifying agents and clinical outcomes in older adults with multiple myeloma.
    Olszewski AJ; Barth PM; Reagan JL
    Cancer Med; 2019 Nov; 8(16):6945-6954. PubMed ID: 31566898
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phenotypic difference of normal plasma cells from mature myeloma cells.
    Harada H; Kawano MM; Huang N; Harada Y; Iwato K; Tanabe O; Tanaka H; Sakai A; Asaoku H; Kuramoto A
    Blood; 1993 May; 81(10):2658-63. PubMed ID: 8490175
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT).
    Durie BGM; Hoering A; Sexton R; Abidi MH; Epstein J; Rajkumar SV; Dispenzieri A; Kahanic SP; Thakuri MC; Reu FJ; Reynolds CM; Orlowski RZ; Barlogie B
    Blood Cancer J; 2020 May; 10(5):53. PubMed ID: 32393732
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Addition of Cyclophosphamide "On Demand" to Lenalidomide and Corticosteroids in Patients With Relapsed/Refractory Multiple Myeloma-A Retrospective Review of a Single-center Experience.
    Alahmadi M; Masih-Khan E; Atenafu EG; Chen C; Kukreti V; Tiedemann R; Trudel S; Reece DE
    Clin Lymphoma Myeloma Leuk; 2019 Apr; 19(4):e195-e203. PubMed ID: 30723035
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thalidomide-based induction regimens are as effective as bortezomib-based regimens in elderly patients with multiple myeloma with cereblon expression.
    Jung SH; Choi HJ; Shin MG; Lee SS; Hwang EC; Jung TY; Cho MS; Yang DH; Ahn JS; Kim YK; Kim HJ; Lee JJ
    Ann Hematol; 2016 Oct; 95(10):1645-51. PubMed ID: 27365142
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Poor outcomes of immunoglobulin D multiple myeloma patients in the era of novel agents: a single-center experience.
    Zhao Q; Li F; Song P; Zhou X; An Z; Mei J; Shao J; Li H; Wang X; Guo X; Zhai Y
    Cancer Commun (Lond); 2019 Sep; 39(1):51. PubMed ID: 31558165
    [No Abstract]   [Full Text] [Related]  

  • 37. CD200 Expression on Plasma Cell Myeloma Cells is Associated with the Efficacies of Bortezomib, Lenalidomide and Thalidomide.
    Tazawa S; Shiozawa E; Homma M; Arai N; Kabasawa N; Kawaguchi Y; Fujiwara S; Okino K; Kobayashi K; Yamochi T; Tate G; Nakamaki T; Takimoto M
    J Clin Exp Hematop; 2015; 55(3):121-6. PubMed ID: 26763359
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Distribution of myeloma plasma cells in peripheral blood and bone marrow correlates with CD56 expression.
    Rawstron A; Barrans S; Blythe D; Davies F; English A; Pratt G; Child A; Morgan G; Jack A
    Br J Haematol; 1999 Jan; 104(1):138-43. PubMed ID: 10027726
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The regulatory mechanism of IL-6-dependent proliferation of human myeloma cells.
    Tsuyama N; Ishikawa H; Abroun S; Liu S; Li FJ; Otsuyama K; Zheng X; Obata M; Taniguchi O; Kawano MM
    Hematology; 2003 Dec; 8(6):409-11. PubMed ID: 14668037
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patient Characteristics and Outcomes of Relapsed/Refractory Multiple Myeloma in Patients Treated with Proteasome Inhibitors in Germany.
    Steinmetz HT; Singh M; Lebioda A; Gonzalez-McQuire S; Rieth A; Schoehl M; Poenisch W
    Oncol Res Treat; 2020; 43(9):449-459. PubMed ID: 32694243
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.